After US FDA Finds ‘Particularly Concerning’ GMP Problems, Homeopathic Firm Continues OTC Sales
A warning letter submitted by FDA Office of Regulatory Affairs’ Division of Pharmaceutical Quality Operations I in New Jersey notes that Homeocare Laboratories indicated to agency officials that it no longer is manufacturing OTC drugs.
You may also be interested in...
Although Washington Homeopathic informed FDA it recalled homeopathics manufactured by a supplier on import alert and would recall “high risk” tinctures, it would allow its customers to decide whether to return other products also identified as potentially adulterated.
Revised draft guidance identifies types of homeopathics posing "higher risks to public health." FDA withdraws 1988 compliance policy guide that allows homeopathic to be available even though they are not subject to pre-market approval or other review process agency imposes on all other drugs.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.